Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer

Inclusion Criteria

• Participants must have histologically or cytologically confirmed invasive breast cancer, with recurrent or metastatic disease; participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
• Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan
• Participants must have recent evidence of progressive disease
• Participants must have received 1-3 prior chemotherapeutic regimens for metastatic breast cancer and must have been off treatment with chemotherapy for at least 14 days before enrollment in the study
• Participants must have discontinued all biologic therapy (including vaccines) at least 14 days before enrollment in the study
• Participants must have discontinued any investigational therapy at least 14 days before enrollment in the study
• Participants may have received prior radiation therapy in either the metastatic or early-stage setting
• Radiation therapy must be completed at least 14 days before enrollment in the study
• Participant must not have received radiation to > 25% of his or her bone marrow within 30 days of starting study treatment
• Eastern Cooperative Oncology Group (ECOG) performance status = = 60%)
• Hemoglobin >= 9.0 g/dL
• Absolute neutrophil count >= 1,500/mcL
• Platelets >= 100,000/mcL
• Total bilirubin = = 60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal
• Either the primary tumor and/or the metastasis must be triple-negative; the invasive tumor must be hormone-receptor poor, defined as estrogen-receptor negative (ER-) and progesterone-receptor negative (PR-), or staining = 2 months after treatment, and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging or computed tomography [CT] scan) during the screening period
• Treatment for brain metastases may include whole-brain radiotherapy, radiosurgery, or a combination as deemed appropriate by the treating physician
• Participants may be taking anti-convulsant medications, which must be non-enzyme-inducing anti-epileptic drugs
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to ARQ 197
• History of congestive heart failure defined as Class II to IV per New York Heart Association (NYHA) classification; active coronary artery disease (CAD); clinically significant bradycardia or other uncontrolled, cardiac arrhythmia defined as >= grade 3 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, or uncontrolled hypertension; myocardial infarction occurring within 6 months prior to study entry (myocardial infarction occurring > 6 months prior to study entry is permitted)
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study
• Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible